OpenURL Connection Search

Select item for more details and to access through your institution.

French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry.
Published in:
British Journal of Haematology, 2024, v. 205, n. 3, p. 990, doi. 10.1111/bjh.19505
By:
- Ferment, B.;
- Lambert, J.;
- Caillot, D.;
- Lafon, I.;
- Karlin, L.;
- Lazareth, A.;
- Touzeau, C.;
- Leleu, X.;
- Moya, N.;
- Harel, S.;
- Perrot, A.;
- Bories, P.;
- Vincent, L.;
- Lamure, S.;
- Mohty, M.;
- Malard, F.;
- Manier, S.;
- Yakoub‐Agha, I.;
- Schiano De Colella, J.‐M.;
- Brisou, G.
Publication type:
Article
Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity.
Published in:
Leukemia (08876924), 2003, v. 17, n. 12, p. 2500, doi. 10.1038/sj.leu.2403175
By:
- Costello, R.T.;
- Mallet, F.;
- Barbarat, B.;
- Schiano de Colella, J.-M.;
- Sainty, D.;
- Sweet, R.W.;
- Truneh, A.;
- Olive, D.
Publication type:
Article
ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.57_2880
By:
- Herbaux, C.;
- Schiano de Colella, J. M.;
- Thieblemont, C.;
- Guidez, S.;
- Ysebaert, L.;
- Tilly, H.;
- Le Gouill, S.;
- Houot, R.;
- Bachy, E.;
- Laurent, C.;
- Damaj, G.;
- Feugier, P.;
- Morineau, N.;
- Tarte, K.;
- Morschhauser, F.;
- Cartron, G.
Publication type:
Article
ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.22_2880
By:
- Cartron, G.;
- Bachy, E.;
- Guidez, S.;
- Gyan, E.;
- Gressin, R.;
- Morineau, N.;
- Sibon, D.;
- Casasnovas, O.;
- Le Gouill, S.;
- Tilly, H.;
- Ysebaert, L.;
- Schiano de Colella, J. M.;
- Feugier, P.;
- Virelizier, E. Nicolas;
- Haioun, C.;
- Damaj, G.;
- Tarte, K.;
- Laurent, C.;
- Houot, R.;
- Thieblemont, C.
Publication type:
Article
RESISTANCE OF B‐CELL LYMPHOMAS TO CAR‐T CELL THERAPY IS ASSOCIATED WITH HISTOPHENOTYPICAL AND GENOMIC TUMOR CHANGES WHICH CAN INDUCE PROFOUND TRANS‐DIFFERENTIATION.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.190_2880
By:
- Laurent, C.;
- Hamon, M.;
- Syrykh, C.;
- de Adélaï, J.;
- Guille, A.;
- Parrens, M.;
- Dartigues, P.;
- Bardet, A.;
- Mescam, L.;
- Schiano De Colella, J.‐M.;
- Sujobert, P.;
- Besson, C.;
- Birnbaum, D.;
- Xerri, L.
Publication type:
Article
PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUP.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.157_2880
By:
- Al Tabaa, Y.;
- Casasnovas, O.;
- Baillet, C.;
- Bachy, E.;
- Virelizier, E. Nicolas;
- Schiano de Colella, J. M.;
- Bailly, C.;
- Kanoun, S.;
- Guidez, S.;
- Gyan, E.;
- Gressin, R.;
- Morineau, N.;
- Ysebaert, L.;
- Le Gouill, S.;
- Tilly, H.;
- Houot, R.;
- Morschhauser, F.;
- Cartron, G.;
- Herbaux, C.
Publication type:
Article

Found: 6

French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry.

Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity.

ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA.

ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA.

RESISTANCE OF B‐CELL LYMPHOMAS TO CAR‐T CELL THERAPY IS ASSOCIATED WITH HISTOPHENOTYPICAL AND GENOMIC TUMOR CHANGES WHICH CAN INDUCE PROFOUND TRANS‐DIFFERENTIATION.

PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUP.